ParkinsonCanadaV1, PubMed, Corpus, bibRecord, 000790

Pimavanserin as treatment for Parkinson's disease psychosis.

Identifieur interne : 000790 ( PubMed/Corpus ); précédent : 000789; suivant : 000791

Pimavanserin as treatment for Parkinson's disease psychosis.

Auteurs : Susan H. Fox

Source :

Lancet (London, England) [ 1474-547X ] ; 2014.

RBID : pubmed:24183566

English descriptors

KwdEn :
- Antiparkinson Agents (therapeutic use), Antipsychotic Agents (therapeutic use), Female, Humans, Male, Parkinson Disease (psychology), Piperidines (therapeutic use), Psychotic Disorders (drug therapy), Serotonin 5-HT2 Receptor Agonists (therapeutic use), Urea (analogs & derivatives), Urea (therapeutic use).
MESH :
- chemical , analogs & derivatives : Urea.
- chemical , therapeutic use : Antiparkinson Agents, Antipsychotic Agents, Piperidines, Serotonin 5-HT2 Receptor Agonists, Urea.
- drug therapy : Psychotic Disorders.
- psychology : Parkinson Disease.
- Female, Humans, Male.

DOI: 10.1016/S0140-6736(13)62157-1
PubMed: 24183566

Links to Exploration step

pubmed:24183566

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Pimavanserin as treatment for Parkinson's disease psychosis.</title>
<author><name sortKey="Fox, Susan H" sort="Fox, Susan H" uniqKey="Fox S" first="Susan H" last="Fox">Susan H. Fox</name>
<affiliation><nlm:affiliation>Movement Disorder Clinic, University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada M5T 2S8. Electronic address: sfox@uhnresearch.ca.</nlm:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2014">2014</date>
<idno type="RBID">pubmed:24183566</idno>
<idno type="pmid">24183566</idno>
<idno type="doi">10.1016/S0140-6736(13)62157-1</idno>
<idno type="wicri:Area/PubMed/Corpus">000790</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000790</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Pimavanserin as treatment for Parkinson's disease psychosis.</title>
<author><name sortKey="Fox, Susan H" sort="Fox, Susan H" uniqKey="Fox S" first="Susan H" last="Fox">Susan H. Fox</name>
<affiliation><nlm:affiliation>Movement Disorder Clinic, University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada M5T 2S8. Electronic address: sfox@uhnresearch.ca.</nlm:affiliation>
</affiliation>
</author>
</analytic>
<series><title level="j">Lancet (London, England)</title>
<idno type="eISSN">1474-547X</idno>
<imprint><date when="2014" type="published">2014</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiparkinson Agents (therapeutic use)</term>
<term>Antipsychotic Agents (therapeutic use)</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Parkinson Disease (psychology)</term>
<term>Piperidines (therapeutic use)</term>
<term>Psychotic Disorders (drug therapy)</term>
<term>Serotonin 5-HT2 Receptor Agonists (therapeutic use)</term>
<term>Urea (analogs & derivatives)</term>
<term>Urea (therapeutic use)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Urea</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Antipsychotic Agents</term>
<term>Piperidines</term>
<term>Serotonin 5-HT2 Receptor Agonists</term>
<term>Urea</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Psychotic Disorders</term>
</keywords>
<keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Female</term>
<term>Humans</term>
<term>Male</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24183566</PMID>
<DateCreated><Year>2014</Year>
<Month>02</Month>
<Day>10</Day>
</DateCreated>
<DateCompleted><Year>2014</Year>
<Month>02</Month>
<Day>25</Day>
</DateCompleted>
<DateRevised><Year>2016</Year>
<Month>11</Month>
<Day>25</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1474-547X</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>383</Volume>
<Issue>9916</Issue>
<PubDate><Year>2014</Year>
<Month>Feb</Month>
<Day>08</Day>
</PubDate>
</JournalIssue>
<Title>Lancet (London, England)</Title>
<ISOAbbreviation>Lancet</ISOAbbreviation>
</Journal>
<ArticleTitle>Pimavanserin as treatment for Parkinson's disease psychosis.</ArticleTitle>
<Pagination><MedlinePgn>494-6</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/S0140-6736(13)62157-1</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0140-6736(13)62157-1</ELocationID>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fox</LastName>
<ForeName>Susan H</ForeName>
<Initials>SH</Initials>
<AffiliationInfo><Affiliation>Movement Disorder Clinic, University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada M5T 2S8. Electronic address: sfox@uhnresearch.ca.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="">Comment</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2013</Year>
<Month>11</Month>
<Day>01</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>Lancet</MedlineTA>
<NlmUniqueID>2985213R</NlmUniqueID>
<ISSNLinking>0140-6736</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010880">Piperidines</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D058826">Serotonin 5-HT2 Receptor Agonists</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>8W8T17847W</RegistryNumber>
<NameOfSubstance UI="D014508">Urea</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>JZ963P0DIK</RegistryNumber>
<NameOfSubstance UI="C510793">pimavanserin</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Lancet. 2014 Feb 8;383(9916):533-40</RefSource>
<PMID Version="1">24183563</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000978" MajorTopicYN="N">Antiparkinson Agents</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName>
<QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010880" MajorTopicYN="N">Piperidines</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058826" MajorTopicYN="N">Serotonin 5-HT2 Receptor Agonists</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014508" MajorTopicYN="N">Urea</DescriptorName>
<QualifierName UI="Q000031" MajorTopicYN="Y">analogs & derivatives</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year>
<Month>11</Month>
<Day>5</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2013</Year>
<Month>11</Month>
<Day>5</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2014</Year>
<Month>2</Month>
<Day>26</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">24183566</ArticleId>
<ArticleId IdType="pii">S0140-6736(13)62157-1</ArticleId>
<ArticleId IdType="doi">10.1016/S0140-6736(13)62157-1</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PubMed/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000790 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000790 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    PubMed
   |étape=   Corpus
   |type=    RBID
   |clé=     pubmed:24183566
   |texte=   Pimavanserin as treatment for Parkinson's disease psychosis.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i   -Sk "pubmed:24183566" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd   \
       | NlmPubMed2Wicri -a ParkinsonCanadaV1

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022

	La maladie de Parkinson au Canada (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson au Canada (serveur d'exploration)

Pimavanserin as treatment for Parkinson's disease psychosis.

Pimavanserin as treatment for Parkinson's disease psychosis.

Source :

English descriptors

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki